<DOC>
<DOCNO>EP-0610303</DOCNO> 
<TEXT>
<INVENTION-TITLE>
SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS AS ANALGESIC AGENTS.
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3155	A61K3155	A61P2500	A61P2504	C07D26700	C07D26714	C07D26720	C07D41300	C07D41312	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61P	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61P25	A61P25	C07D267	C07D267	C07D267	C07D413	C07D413	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
SEARLE 
&
 CO
</APPLICANT-NAME>
<APPLICANT-NAME>
G.D. SEARLE 
&
 CO.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
HAGEN TIMOTHY JOSEPH
</INVENTOR-NAME>
<INVENTOR-NAME>
HALLINAN E ANN
</INVENTOR-NAME>
<INVENTOR-NAME>
HUSA ROBERT KNOL
</INVENTOR-NAME>
<INVENTOR-NAME>
HAGEN, TIMOTHY, JOSEPH
</INVENTOR-NAME>
<INVENTOR-NAME>
HALLINAN, E., ANN
</INVENTOR-NAME>
<INVENTOR-NAME>
HUSA, ROBERT, KNOL
</INVENTOR-NAME>
</INVENTORS>
<DESCRIPTION>
 SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS AS ANALGESIC AGENTSBACKGROUND OF THE INVENTION(1) Field of the InventionThe present invention generally relates to 5 compounds having pharmacological activity which are useful as pharmacological agents and, more particularly, as analgesic agents for the treatment of pain, to pharmaceutical compositions containing one or more of these compounds, and to methods of treatment 10 employing these compounds. More particularly, the present invention concerns substituted dibenzoxazepine compounds, pharmaceutical compositions containing one or more of these compounds in combination with a pharmaceutically-acceptable carrier, and methods of 15. treating pain employing these compounds.Analgesic compounds are agents which alleviate pain without causing a loss of consciousness and, thus, which are useful for treating pain and, often, for reducing inflammation. 20 The major classes of analgesic compounds include narcotic analgesics, or opiates, compounds which alleviate pain and induce sleep, and analgesic- antipyretic compounds, compounds which alleviate pain and reduce fever, such as salicylates. 5 Although the efficacy of opiates in relieving pain is well established, the associated addiction liability of opiates is a distinct disadvantage of these compounds.While salicylate and salicylate-like agents (non- 0 steroidal antiinflammatory agents or NSAIDS) are also efficacious in relieving pain, they often exhibit undesirable side effects, such as gastrointestinal irritation, as with aspirin, allergic response, as with aspirin, and/or liver toxicity with extended use, as 5 with acetaminophen.SUBSTITUTE SHEE1 

 The compounds of the present invention are neither opiates nor salicylates, and represent another class of compounds which are useful as analgesic agents.(2) Description of the Related ArtU.S. Patent Nos. 4,559,336 and 4,614,617 (a continuation-in-part of U.S. 4,559,336) disclose 8-chlorodibenz[b,f] [l,4]oxazepine-10(11H)-carboxylic acid, 2-(sulfinyl- and sulfonyl-containing acyl) ydrazides, and intermediates thereof.U.S. Patent No. 3,534,019 discloses hydrazides of dibenzoxazepine-, dibenzothiazepine- and dibenzodiazepine- carboxylic acids.U.S. Patent No. 3,624,104 discloses aralkanoyl derivatives of dibenzoxazepine-N-carboxylic acid hydrazide compounds.U.S. Patent No. 3,989,719 discloses N,N'-diacyl hydrazines.U.S. Patents Nos. 3,917,649 and 3,992,375 (a divisional of U.S. Patent No. 3,917,649) disclose dibenzoxazepine N-carboxylic acid hydrazine compounds.U.S. Patents
</DESCRIPTION>
<CLAIMS>
WHAT IS CLAIMED IS:
1. A compound having a structure of the formula:
or a pharmaceutically-acceptable salt thereof, wherein:
X: is -NH- or -CH
2
-;
Y is: (1) -CH
2
- when X is -NH-, and (2) -NH- when X is -CH
2
-;
R
1
 is: hydrogen, halogen or -OR
4
; o R* is: hydrogen, alkyl or -C "-R8
β
;
Z is: oxygen, sulfur, -SO-, -S0
2
- or -NR
5
-;
R
5
 is: hydrogen or t-butyloxycarbonyl;
R
2
 is: hydrogen, halogen or trifluoromethyl;
R
3
 is: hydrogen, halogen, aryl, heteroaryl or -NR
6
R
7
;
R
6
 and R
7
 are: each independently hydrogen or alkyl; 


 R
8
 is: alkyl, aryl or 

R
9
 and R
10
 are: each independently hydrogen or alkyl, or can combine together to form N-morpholino or 4-methyl-N- piperazinyl;
m and n are: each independently integers of from 0 to 3; and
P is: 0 or 1, provided that p is not 1 when m is 0.
2. A compound of Claim 1 wherein R
1
 is hydrogen.
3. A compound of Claim 2 wherein Z is sulfur, -S0
2
- or -NR
5
-.
4. A compound of Claim 3 wherein R
2
 is halogen and R
5
 is hydrogen.
5. A compound of Claim 4 wherein R
6
 and R
7
 are both hydrogen, or are both methyl.
6. A compound of Claim 5 wherein m is 2.
7. A compound of Claim 6 wherein R
3
 is hydrogen, aryl, heteroaryl or -NR
6
R
7
.
8. A compound of Claim 7 wherein R
3
 is hydrogen, heteroaryl or -NR
6
R
7
.
9. A compound of Claim 8 wherein R
3
 is hydrogen, furan, thiophene, pyridine or -NR
6
R
7
.
SUBSTITUTESHEET 


 10. A compound of Claim 1, wherein the compound
11. A compound of Claim 1, wherein the compound is:
SUBSTITUTE SHEET 


 12. A compound of Claim 1, wherein the compound is:
13. A compound of Claim 1, wherein the compound is:
SUBSTITUTESHEE
"

 14. A compound of Claim 1, wherein the compound is:
15. A compound of Claim 1, wherein the compound is:
+HC1
SUBSTITUTESHEET 


 16. A compound of Claim 1, wherein the compound is:
17. A compound of Claim 1, wherein the compound is:
SUBSTITUTESHEET 


 18. A compound of Claim 1, wherein the compound is:
19. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a therapeutically-effective amount of a compound of Claim 1.
20. The pharmaceutical composition of Claim 19 wherein the compound is:
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3-
(ethylsulfonyl) ropanamide;
N-[2-(8-chloro-10,11-dihydrodibenz- [b, ][1, ]
oxazepin-10-yl)-2-oxoethyl]-3- [(2-furanylmethyl)thio]
propanamide;
N-[2-(8-chloro-10,11-dihydrodibenz- [b,f][l,4]
oxazepin-10-yl)-2-oxoethyl]-4- pyridinepropanamide, monohydrochloride; 



 N- [ 2- (8-chlorodibenz-10-ll-dihydrobenz-
[b,f] [1,4]
oxazepin-10-y1)-2-oxoethyl]-3-
[ (2-thienylmethyl)thio]propanamide;
3-Amino-N-[2-(8-chloro-10,ll- dihydrodibenz[b,f] [1,4]
oxazepin-10-y1)-2-oxoethy1]- propanamide, monohydrochloride;
N-[2-(8-chloro-10,11-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3-
[[2-(dimethylamino)ethyl]thio]
 ropanamide , monohydrochloride;
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3-
[ (2-thienylmethyl)amino]propanamide, monohydrochloride;
8-chloro-N-[4-(ethylsulfonyl)-2- oxobutyl]dibenz[b,f]
 [1,4]oxazepin-10(11H)-carboxamide; or
8-chloro-N-[4-[ (2-furanylmethy1)thio]- 2-oxobuty1]
dibenz[b,f] [1,4]
oxazepin-10(11H)- carboxamide.
21. A method for treating central nervous disorders in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
22. The method of Claim 21 wherein the compound is:
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3-
(ethylsulfonyl)propanamide;
SUBSTITUTE SHEE T7 


 N-[2-(8-chloro-10,ll-dihydrodibenz-
[b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3-
[(2-furanylmethyl)thio]propanamide;
N-[2-(8-chloro-lθ,ll-dihydrodibenz-
[b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-4- pyridinepropanamide, monohydrochloride;
N-[2-(8-chlorodibenz-10-ll-dihydrobenz- [b,f][l,4]
oxazepin-10-yl)-2-oxoethyl]-3-
[(2-thienylmethyl)thio]propanamide;
3-Amino-N-[2-(8-chloro-10,11- dihydrodibenz[b,f] [1,4]
oxazepin-10-yl)-2-oxoethyl]- propanamide, monohydrochloride;
N-[2-(8-chloro-10,11-dihydrodibenz- [b, ][l,4]
oxazepin-10-yl)-2-oxoethyl]-3- . [[2-(dimethyla ino)ethyl]
thio]propanamide, monohydrochloride;
N-[2-(8-chloro-10,11-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [(2-thienylmethyl)amino]
propanamide, monohydrochloride;
8-chloro-N-[4-(ethylsulfonyl)-2- oxobutyl]dibenz[b,f]
[l,4]oxazepin-10(11H)-carboxamide; or
8-chloro-N-[4-[(2-furanylmethyl)thio]- 2-oxobutyl]
dibenz[b,f][I,4]
oxazepin-10(11H)- carboxamide.
23. A method for treating pain in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
SUBSTITUTESHEET 


 24. The method of Claim 23 wherein the compound is:
N-[2-(8-chloro-10,1l-dihydrodibenz-
[b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3-
(ethylsulfonyl)propanamide;
N-[2-(8-chloro-10,ll-dihydrodibenz-
[b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3-
[ (2-furanylmethy1)thio]propanamide;
N-[2-(8-chloro-10,11-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-4- pyridinepropanamide, monohydrochloride;
3-Amino-N-[2-(8-chloro-10,ll- dihydrodibenz[b,f] [1,4]
oxazepin-10-yl)-2-oxoethyl]- propanamide, monohydrochloride;
N-[2-(8-chloro-10 ,11-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3-
[[2-(dimethylamino)ethyl]thio]
propanamide, monohydrochloride;
8-chloro-N-[4-(ethylsulfonyl)-2- oxobutyl]dibenz[b,f]
 [I,4]oxazepin-10(11H)-carboxamide; or
8-chloro-N-[4-[ (2-furanylmethyl)thio]~ 2-oxobutyl]
dibenz[b,f] [l,4]
oxazepin-10(11H)- carboxamide.
SUBSTITUTESHEET 


 25. A method for treating enuresis in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
26. The method of Claim 25 wherein the compound
1SΪ
N-[2-(8-chloro-10,11-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- (ethylsulfonyl)propanamide;
N-[2-(8-chloro-10,11-dihydrodibenz- [b,f][l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [(2-furanylmethyl)thio]
propanamide;
N-[2-(8-chloro-10,11-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-4- pyridinepropanamide, monohydrochloride;
N-[2-(8-chlorodibenz-10-ll-dihydrobenz-
[b,f][l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [(2-thienylmethyl)thio]
propanamide;
3-Amino-N-[2-(8-chloro-10,11- dihydrodibenz[b,f] [1,4]
oxazepin-10-yl)-2-oxoethyl]- propanamide, monohydrochloride;
N-[2-(8-chloro-10,11-dihydrodibenz- [b,f][1, ]
oxazepin-10-yl)-2-oxoethyl]-3- [[2-(dimethylamino)ethyl]
thio]propanamide, monohydrochloride;
N-[2-(8-chloro-10,11-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [(2-thienylmethyl)amino]
propanamide, monohydrochloride;
8-chloro-N-[4-(ethylsulfonyl)-2- 


 oxobutyl]dibenz[b,f]
 [1,4]oxazepin-10(11H)-carboxamide; or
8-chloro-N-[4-[(2-furanylmethyl)thio]- 2-oxobutyl]
dibenz[b,f] [I,4]
oxazepin-10(11H)- carboxamide.
27. A method for treating dysmenorrhea in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
28. The method of Claim 27 wherein the compound is:
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- (ethylsulfonyl)propanamide;
N-[2-(8-chloro-10,ll-dihydrodibenz-
[b,f] [1,4]
oxazepin-10-y1)-2-oxoethyl]-3-
[(2-furanylmethyl)thio]propanamide;
N-[2-(8-chloro-10,11-dihydrodibenz-
[b,f] [1,4]
oxazepin-10-y1)-2-oxoethy1]-4- pyridinepropanamide, monohydrochloride;
N-[2-(8-chlorodibenz-10-ll-dihydrobenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3-
[ (2-thienylmethyl)thio]propanamide;
SUBSTITUTE SHEET 


 3-Amino-N-[2- (8-chloro-10 , ll- dihydrodibenzEb,f] [1,4]
oxazepin-10-yl)-2-oxoethyl]
•
 propanamide, monohydrochloride;
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [1,4]
oxazepin-10-yl)-2-oxoethyl]-3- [[2-(dimethylamino)ethyl]
thio]propanamide, monohydrochl
oride;
N-[2-(8-chloro-10,ll-dihydrodibenz-
[b,f][1,4]
oxazepin-10-yl)-2-oxoethyl]-3-
[(2-thienylmethyl)amino]propanamide, monohydrochloride;
8-chloro-N-[4-(ethylsulfonyl)-2- oxobutyl]dibenz[b,f]
 [1,4]oxazepin-10(11H)-carboxamide; or
8-chloro-N-[4-[(2-furanylmethyl)thio]- 2-oxobutyl]
dibenz[b,f] [I,4]
oxazepin-10(11H)- carboxamide.
29. A method for treating osteoporosis in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
30. The method of Claim 29 wherein the compound is: N-[2-(8-chloro-10,11-dihydrodibenz-
[b,f] [1,4]
oxazepin-10-yl)-2-oxoethyl]-3- (ethylsulfonyl)propanamide;
N-[2-(8-chloro-10,11-dihydrodibenz- [b,f][l,4]
oxazepin-10-yl)-2-oxόethyl]-3-
[(2-furanylmethyl)thio]propanamide;
SUBSTITUTESHEET 


 N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-4- pyridinepropanamide, monohydrochloride;
N-[2-(8-chlorodibenz-10-ll-dihydrobenz-
[b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [ (2-thienylmethyl)thio]
propanamide;
3-Amino-N-[2-(8-chloro-10 ,11- dihydrodibenz[b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]- propanamide, monohydrochloride;
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [1 ,4]
oxazepin-10-yl)-2-oxoethyl]-3- [[2-(dimethylamino)ethyl]
thio]propanamide , monohydrochloride;
N-[2-(8-chloro-l0,11-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [ (2-thienylmethyl)amino]
propanamide, monohydrochloride;
8-chloro-N-[4-(ethylsulfonyl)-2- oxobutyl]dibenz[b,f]
 [1,4]oxazepin-10(11H)-carboxamide; or 8-chloro-N-[4-[ (2-furanylmethyl)thio]
-
2-oxobutyl]dibenz[b,f]
 [l ,4]oxazepin-10(HH)- carboxamide.
31. A method for treating convulsions in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
32. The method of Claim 31 wherein the compound is:
SUBSTITUTE SHEET 


 N-[2-(8-chloro-10,ll-dihydrodibenz-
[b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3-
(ethylsulfonyl) ropanamide;
N-[2-(8-chloro-10,11-dihydrodibenz-
[b,f][l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [(2-furanylmethyl)thio]
propanamide;
N-[2-(8-chloro-10,11-dihydrodibenz- [b,f [l,4]oxazepin-10-yl)-2-oxoethyl]
-4- pyridinepropanamide, monohydrochloride;
N-[2-(8-chlorodibenz-10-ll-dihydrobenz- [b,f][1,4]
oxazepin-10-yl)-2-oxoethyl]-3- [(2-thienylmethyl)thio]
propanamide;
3-Amino-N-[2-(8-chloro-10,11- dihydrodibenz[b,f][l,4]
oxazepin-10-yl)-2-oxoethyl]• propanamide, monohydrochloride;
N-[2-(8-chloro-lO,ll-dihydrodibenz- [b,f][1,4]
oxazepin-10-yl)-2-oxoethyl]-3- [[2-(dimethylamino)ethyl]
thio]propanamide, monohydrochloride;
N-[2-(8-chloro-10,ll-dihydrodibenz-
[b,f][l,4]
oxazepin-10-yl)-2-oxoethyl]-3-
[(2-thienylmethyl)amino]propanamide, monohydrochloride;
8-chloro-N-[4-(ethylsulfonyl)-2- oxobutyl]dibenz[b,f]
[1,4]oxazepin-10(11H)-carboxamide; or
8-chloro-N-[4-[(2-furanylmethyl) hio]- 2-oxobutyl]
dibenz[b,f] [l,4]
oxazepin-10(11H)- carboxamide.
SUBSTITUTE SHEET 


 33. A method for treating ischemia in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
34. The method of Claim 33 wherein the compound is:
N-[2-(8-chloro-10,11-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- (ethylsulfonyl)propanamide;
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [ (2-furanylmethyl)thio]
propanamide;
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-4- pyridinepropanamide, monohydrochloride;
N-[2-(8-chlorodibenz-10-ll-dihydrobenz-
[b,f] [l,4]
oxazepin-10-yl)-2-oxoethy1]-3- [ (2-thienylmethyl)thio]
propanamide;
3-Amino-N-[2-(8-chloro-10 ,11- dihydrodibenz[b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]- propanamide, monohydrochloride;
N-[2-(8-chloro-10,11-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [ [2-(dimethylamino)ethyl]
thio]propanamide, monohydrochloride;
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [(2-thienylmethyl)amino]
propanamide, monohydrochloride;
SUBSTITUTESHEET 


 8-chloro-N-[4-(ethylsulfonyl)-2- oxobutyl]dibenz[b,f]
 [1,4]oxazepin-10(11H)-carboxamide; or
8-chloro-N-[4-[(2-furanylmethyl)thio]-
2-oxobutyl]dibenz[b,f]
[1,4]oxazepin-10(11H)- carboxamide.
35. A method for treating urinary incontinence in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
36. The method of Claim 35 wherein the compound s:
N-[2-(8-chloro-l0,ll-dihydrodibenz-
[b, ][1, ]
oxazepin-10-yl)-2-oxoethyl]-3-
(ethylsulfonyl) ropanamide;
N-[2-(8-chloro-lO,ll-dihydrodibenz-
[b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [(2-furanylmethyl)thio]
propanamide;
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f][l,4]
oxazepin-10-yl)-2-oxoethyl]-4- pyridinepropanamide, monohydrochloride;
N-[2-(8-chlorodibenz.-10-ll-dihydrobenz- [b,f][1,4]
oxazepin-10-yl)-2-oxoethyl]-3- [(2-thienylmethyl)thio]
propanamide;
3-Amino-N-[2-(8-chloro-ip,11- dihydrodibenz[b,f] [1,4]
oxazepin-10-yl)-2-oxoethyl]• propanamide, monohydrochloride;
SUBSTITUTE SHEET 


 N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [[2-(dimethylamino)ethyl]
thio]propanamide, monohydrochloride;
N-[2-(8-chloro-10,ll-dihydrρdibenz-
[b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3-
[ (2-thienylmethyl)amino]propanamide, monohydrochloride;
8-chloro-N-[4-(ethylsulfonyl)-2- oxobutyl]dibenz[b,f]
 [1,4]oxazepin-10(11H)-carboxamide; or
8-chloro-N-[4-[ (2-furanylmethyl)thio]- 2-oxobutyl]
dibenz[b,f] [l,4]
oxazepin-10(11H)- carboxamide.
37. A method for treating gastric hypermotility in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
38. The method of Claim 37 wherein the compound is: N-[2-(8-chloro-lO,11-dihydrodibenz-
[b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- (ethylsulfonyl)propanamide;
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethy1]-3-
[ (2-furanylmethyl)thio]propanamide;
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [1,4]
oxazepin-10-yl)-2-oxoethyl]-4- pyridinepropanamide, monohydrochloride;
N-[2-(8-chlorodibenz-10-ll-dihydrobenz-
SUBSTITUTESHEET 


 [b,f [1,4]oxazepin-10-yl)-2-oxoethyl]
-3- [(2-thienylmethyl)thio]propanamide;
3-Amino-N-[2-(8-chloro-10,11- dihydrodibenz[b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]- propana ide, monohydrochloride;
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [[2-(dimeth
ylamino) thyl]thio]
propanamide, monohydrochloride;
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f][l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [(2-thienylmethy1)amino]
propanamide, monohydrochloride;
8-chloro-N-[4-(ethylsulfonyl)-2- oxobutyl]dibenz[b,f]
[1,4]oxazepin-10(11H)-carboxamide; or
8-chloro-N-[4-[(2-furanylmethyl)thio -
2-oxobutyl]dibenz[b,f]
[l,4]oxazepin-10(11H)- carboxamide.
39. A method for treating irritable bowel syndrome in an animal comprising administering to said animal a therapeutically-effective amount of a compound of Claim 1.
40. The method of Claim 39 wherein the compound is:
N-[2-(8-chloro-10,11-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- (ethylsulfonyl)propanamide;
N-[2-(8-chloro-10,11-dihydrodibenz-
BSTITUTE SHEET 


 [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [ (2-furanylmethyl)thio]
propanamide;
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-4- pyridinepropanamide, monohydrochloride;
N-[2-(8-chlorodibenz-10-ll-dihydrobenz- [b,f] [l,4]
oxazepin-l0-yl)-2-oxoethy1]-3- [ (2-thienylmethyl)thio]
propanamide;
3-Amino-N-[2-(8-chloro-10,11- dihydrodibenz[b,f] [1,4]
oxazepin-10-yl)-2-oxoethy1]• propanamide, monohydrochloride;
N-[2-(8-chloro-10,ll-dihydrodibenz- [b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3- [[2-(dimethylamino)ethyl]
thio]propanamide, monohydrochloride;
N-[2-(8-chloro-10,ll-dihydrodibenz-
[b,f] [l,4]
oxazepin-10-yl)-2-oxoethyl]-3-
[(2-thienylmethyl)amino]propanamide, monohydrochloride;
8-chloro-N-[4-(ethylsulfonyl)-2- oxobutyl]dibenz[b,f]
 [1,4]oxazepin-10(11H)-carboxamide; or
8-chloro-N-[4-[ (2-furanylmethyl)thio]- 2-oxobutyl]
dibenz[b,f] [I,4]
oxazepin-10(11H)- carboxamide.
SUBSTITUTE SHEET 

</CLAIMS>
</TEXT>
</DOC>
